Objective: To establish methods to examine the polar lipids of triglyceride-rich lipoproteins (TRLs) and to examine postprandial changes in glycerophosphocholine (PC) and glycerophosphoethanolamine (PE) polar lipids and in the ratio of diacyl to alkenylacyl components. The membrane phospholipids of TRLs have received little attention. PC and PE constitute major fractions and both comprise diacyl- and alkenylacyl-phospholipids. There has been recent interest in possible antioxidant properties of alkenylacyl (plasmalogen) PE.
Design: Analysis of PE and PC fractions in blood samples taken from the subjects while fasting and at four 2-h intervals after eating a 4749-kJ breakfast.
Participants: Five healthy subjects.
Outcome Measures: Levels of PE and PC fractions isolated from blood samples by ultracentrifugation (to isolate the d < 1.006 fraction of plasma) and reversed-phase chromatography.
Results: The concentration of triglyceride in particles of density less than 1.006 g/cm2 in the samples increased rapidly, peaking 4 h after the meal at 0.51 mmol/L above the fasting level. Apolipoprotein B-48 was maximal in the sample taken 2 h after eating and below 1%, as a percentage of apolipoproteins B-48 and B-100, in all other samples. The concentration of PC exceeded that of PE by an order of magnitude, but there was a proportionately greater increase in PE postprandially. PE contained a rapidly cleared alkenylacyl fraction, which was maximal (at a threefold increase over the baseline level) in the sample taken 4 h after eating.
Conclusions: As blood triglyceride levels rise and fall postprandially, the polar lipid composition of the TRLs also changes; these changes are more marked in the PE than in the PC fraction. The fact that the level of the PE fraction peaked later (at 4 h after eating) than that of B-48 apolipoprotein (which peaked at 2 h after eating) suggests that the peak in the PE fraction had a hepatic (very-low-density lipoprotein) origin. Alkenylacyl (plasmalogen) phospholipid accompanied both PE and PC fractions but was about 10 times greater in PE. This result is significant if alkenylacyl PE does indeed function as an antioxidant.
Download full-text PDF |
Source |
---|
Clin Nutr ESPEN
January 2025
Department of Sport Sciences, Faculty of Humanities, University of Kashan, Kashan, Iran.
Introduction: We performed a systematic review and meta-analysis to investigate the effects of combining omega-3 polyunsaturated fatty acids (n-3 PUFAs) supplementation with exercise training, as compared to exercise training alone, on body composition measures including body weight, body mass index (BMI), fat mass, body fat percentage, and lean body mass. Additionally, we determined the effects on cardiometabolic health outcomes including lipid profiles, blood pressure, glycemic markers, and inflammatory markers.
Method: Three primary electronic databases including PubMed, Web of Science, and Scopus were searched from inception to April 5, 2023 to identify original articles comparing n-3 PUFA supplementation plus exercise training versus exercise training alone, that investigated at least one of the following outcomes: fat mass, body fat percentage, lean body mass, triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), systolic (SBP) and diastolic (DBP) blood pressures, fasting glucose and insulin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α).
Arch Biochem Biophys
January 2025
Department of Cardiology, Zhongnan Hospital of Wuhan University, No 169 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China. Electronic address:
Background: Astaxanthin (ASX), a fat-soluble carotenoid mainly sourced from Haematococcus pluvialis, shows promise for clinical applications in chronic inflammatory diseases. This study investigates whether ASX can mitigate atherosclerosis (AS) by modulating macrophage ferroptosis and provides astaxanthin-loaded polylactic acid-glycolic acid nanoparticles (ASX-PLGA NPs) as comparison.
Method: ApoE-/- mice were fed a high-fat diet with ASX or statin intervention.
J Formos Med Assoc
January 2025
Kutahya Health Sciences University, Faculty of Medicine, Department of Cardiology, Kutahya, Turkey. Electronic address:
Curr Cardiol Rep
January 2025
John Ochsner Heart and Vascular Institute, Ochsner Clinical School University of Queensland School of Medicine, New Orleans, LA, USA.
Purpose Of Review: To provide a narrative overview of trends and disparities in the cardiometabolic profiles of U.S. adults by synthesizing findings from nationally representative studies conducted between 1999 and 2020.
View Article and Find Full Text PDFAm J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Oral bempedoic acid (NEXLETOL in the USA; Nilemdo in the EU) and the fixed dose combination (FDC) of bempedoic acid/ezetimibe (NEXLIZET in the USA; Nustendi in the EU) are approved to reduce cardiovascular (CV) risk in statin-intolerant patients who are at high risk for, or have, CV disease. A first-in-class therapy, bempedoic acid inhibits the adenosine triphosphate-citrate lyase enzyme in the cholesterol biosynthesis pathway. In the multinational phase III CLEAR Outcomes trial in statin-intolerant patients, once-daily bempedoic acid 180 mg significantly reduced the risk of the primary endpoint (a four-component major adverse CV event composite of CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization) compared with placebo.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!